Monte Rosa Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Monte Rosa Therapeutics şirketinin toplam hissedar öz sermayesi $205.5M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $315.1M ve $109.6M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$242.19m
Eşitlik	US$205.46m
Toplam yükümlülükler	US$109.62m
Toplam varlıklar	US$315.08m

Son finansal sağlık güncellemeleri

We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth

Sep 23

Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth

Mar 20

Here's Why We're Watching Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation

Sep 29

Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?

May 01

We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate

Jan 16

We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth

Oct 01

Recent updates

News Flash: Analysts Just Made A Sizeable Upgrade To Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Forecasts

Nov 12

Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash

Oct 28

We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth

Sep 23

Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth

Mar 20

Here's Why We're Watching Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation

Sep 29

Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?

May 01

We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate

Jan 16

We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth

Oct 01

Monte Rosa Therapeutics rises 9% after FDA clears application for human trial of lung cancer treatment

Sep 06

We're Hopeful That Monte Rosa Therapeutics (NASDAQ:GLUE) Will Use Its Cash Wisely

Jun 17

We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth

Mar 04

We're Not Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn

Sep 24

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: GLUE 'nin kısa vadeli varlıkları ( $251.2M ) kısa vadeli yükümlülüklerini ( $41.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: GLUE şirketinin kısa vadeli varlıkları ( $251.2M ) uzun vadeli yükümlülüklerini ( $68.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: GLUE borçsuzdur.

Borcun Azaltılması: GLUE un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: GLUE şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: GLUE serbest nakit akışı her yıl % 8.1 1.9 yıl yetecek nakit akışına sahip olacaktır.

Monte Rosa Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth

Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth

Here's Why We're Watching Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation

Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?

We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate

We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth

Recent updates

Consensus revenue estimates increase by 379%

News Flash: Analysts Just Made A Sizeable Upgrade To Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Forecasts

Board Member notifies of intention to sell stock

Price target increased by 7.8% to US$15.71

Consensus revenue estimates increase by 16%

Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash

We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth

New major risk - Share price stability

Consensus revenue estimates increase by 75%

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

Monte Rosa Therapeutics, Inc. Announces Executive Promotions

Monte Rosa Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000836 million.

Monte Rosa Therapeutics, Inc. has filed a Follow-on Equity Offering.

New minor risk - Shareholder dilution

Monte Rosa Therapeutics, Inc. Announces Departure of Owen Wallace as Chief Scientific Officer and Transition to Member of its Scientific Advisory Board

New minor risk - Shareholder dilution

Monte Rosa Therapeutics, Inc., Annual General Meeting, Jun 12, 2024

Consensus estimates of losses per share improve by 12%

Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth

Monte Rosa Therapeutics, Inc. Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1b Pathway Inhibitor

New major risk - Share price stability

Price target decreased by 11% to US$16.50

Monte Rosa Therapeutics, Inc. has announced a Derivatives Offering in the amount of $25 million.

Monte Rosa Therapeutics, Inc. has announced a Derivatives Offering in the amount of $25 million.

Price target decreased by 16% to US$18.50

Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors

New minor risk - Share price stability

Here's Why We're Watching Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation

Monte Rosa Therapeutics, Inc. Appoints Anthony M. Manning to the Board of Directors

Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, A Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases

Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?

We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate

Price target decreased to US$21.89

High number of new and inexperienced directors

Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359

We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth

Monte Rosa Therapeutics rises 9% after FDA clears application for human trial of lung cancer treatment

Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 2000 Growth Index

We're Hopeful That Monte Rosa Therapeutics (NASDAQ:GLUE) Will Use Its Cash Wisely

High number of new directors

Monte Rosa Therapeutics, Inc. Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022

We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth

High number of new directors

We're Not Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn

Monte Rosa Therapeutics, Inc. has completed an IPO in the amount of $222.3 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin